{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-002786","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.175064+00:00","generated_at":"2026-06-19T13:37:01.524159+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adaptive Biotechnologies Q4 revenue $55.2M (+46% YoY); guides FY2023 rev $205M-$215M","bullets":["Full year 2022 revenue $185.3M (+20% YoY); MRD revenue $87.1M (+32%), Immune Medicine $98.2M (+11%).","clonoSEQ test volume Q4 up 54% to 10,526 tests; full year up 51% to 36,871 tests.","Net loss Q4 $40.2M vs $61.4M; adjusted EBITDA loss $19.6M vs $44.9M YoY.","2023 revenue guidance $205M-$215M; operating expenses expected below $385.5M.","Long-term targets: 20-30% revenue CAGR, positive adjusted EBITDA in 2025, cash flow breakeven in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-002786","json":"https://secwatch.observer/filing/0000950170-23-002786.json","markdown":"https://secwatch.observer/filing/0000950170-23-002786.md","text":"https://secwatch.observer/filing/0000950170-23-002786.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000095017023002786/0000950170-23-002786-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000095017023002786/adpt-20230214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T13:37:01.524159+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2702c970b03705307e5708b05d4a28db41851de1","claim":"Adaptive Biotechnologies Corp reported full year 2023 results: revenue $205 million to $215 million. Guidance initiated.","evidence_excerpt":"Adaptive Biotechnologies expects full year 2023 revenue to be in the range of $205 million to $215 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000095017023002786/0000950170-23-002786-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$205 million to $215 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"4ca4c87ddae7c38183235b9c3e0a99b830b0d2c7","claim":"Adaptive Biotechnologies Corp reported full year ended December 31, 2022 results: revenue $185.3 million, net income Net loss was $200.4 million.","evidence_excerpt":"Revenue was $185.3 million for the year ended December 31, 2022, representing a 20% increase from the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000095017023002786/0000950170-23-002786-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2022"},{"label":"Revenue","value":"$185.3 million"},{"label":"Net income","value":"Net loss was $200.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"64f4819dc3f3bb27ffb9467655386933f8556617","claim":"Adaptive Biotechnologies Corp reported fourth quarter ended December 31, 2022 results: revenue $55.2 million, net income Net loss was $40.2 million.","evidence_excerpt":"Revenue was $55.2 million for the quarter ended December 31, 2022, representing a 46% increase from the fourth quarter in the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000095017023002786/0000950170-23-002786-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$55.2 million"},{"label":"Net income","value":"Net loss was $40.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}